Drug intelligence / Profile preview

ledasorexton

Development stage: Unknown
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

Ledasorexton (E2086) is an orally bioavailable, selective orexin receptor type 2 (OX2R) agonist developed by Eisai. It is designed to promote wakefulness and control cataplexy by compensating for the loss of orexin-producing neurons, which is the underlying pathophysiology of narcolepsy. In clinical trials, ledasorexton has demonstrated the ability to significantly increase daytime wakefulness and reduce cataplexy-like episodes. It is currently in Phase 2 clinical development for the treatment of narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).

Targets

HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on ledasorexton.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ledasorexton.

Explore the full profile